Company Profile

Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury.

Industry Classifications

Sector:
Healthcare

Industry:
Biotechnology

NAICS:
Pharmaceutical Preparations (325412)

SIC:
Pharmaceutical Preparations (2834)

Contact Information

Investor Relations
T: 650-543-5470
ir@unicycive.com

Company Contact
Unicycive Therapeutics, Inc.
4300 El Camino Real
Suite 210
Los Altos, CA 94022
T: 650-351-4495
info@unicycive.com